Every Form 4 that Sagimet Biosciences Inc. Series A (SGMT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SGMT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGMT filings page.
Sagimet Biosciences Inc. director George Kemble reported option exercises and a share sale in Series A Common Stock. On August 14, 2026, he exercised stock options covering 326,618 and 24,369 shares at an exercise price of $6.36 per share, receiving the same number of Series A Common shares. That same day, he sold 350,987 Series A Common shares at a weighted average price of $10.2328 per share, in multiple trades between $9.95 and $10.57. These transactions were conducted under a Rule 10b5-1 trading plan adopted on August 21, 2025, and the option was fully vested and exercisable as of the transaction date.
Sagimet Biosciences Inc. director George Kemble reported an option exercise-and-sale transaction in Series A Common Stock. On August 11, 2026, he exercised stock options covering 20,206 shares at an exercise price of $6.36 per share and received an equivalent number of Series A Common shares. On the same date, he sold 20,206 shares of Series A Common Stock at a weighted average price of $9.9548 per share in multiple trades priced between $9.95 and $9.99. The filing states these transactions were effected under a Rule 10b5-1 trading plan adopted on August 21, 2025, and that the options involved were fully vested and exercisable as of the transaction date.
Sagimet Biosciences Inc. President & CEO David Happel sold 64,051 shares of Series A Common Stock on July 20, 2026 at a weighted average price of $7.7605 per share to cover tax withholding obligations from vesting restricted stock units. These automatic, non-discretionary sales occurred in multiple trades between $7.76 and $7.94 and left him holding 741,570 shares directly.
Sagimet Biosciences Inc. reported that Chief Legal & Admin. Officer Elizabeth Rozek sold 10,545 shares of Series A Common Stock on July 20, 2026, at a weighted average price of $7.7603 per share in transactions between $7.76 and $7.88.
The report states that these shares were automatically sold to cover tax withholding obligations related to vesting restricted stock units and were not at Rozek’s discretion. After these sales, she directly holds 224,414 shares of Sagimet stock.
George Kemble, a director of Sagimet Biosciences Inc., sold 18,844 shares of Series A Common Stock on July 20, 2026, at a weighted average price of $7.4575 per share in open-market or private transactions under a Rule 10b5-1 trading plan adopted on August 21, 2025. After these sales, he directly holds 62,161 shares. The reported trades occurred at prices ranging from $7.17 to $7.97 per share.
Sagimet Biosciences director Beth C. Seidenberg received a grant of stock options covering 39,567 shares of Series A common stock on June 12, 2026. The options have an exercise price of $6.48 per share and expire on June 11, 2036.
These options were awarded as a compensation grant, not a market purchase or sale. According to the terms, the underlying shares will vest in twelve equal monthly installments after June 12, 2026, as long as she continues serving the company on each vesting date.
Sagimet Biosciences Inc. director Paul W. Hoelscher received a grant of stock options covering 39,567 shares of Series A Common Stock. The options have an exercise price of $6.48 per share and expire on June 11, 2036.
The award was granted at no cost to him and is structured as compensation, not an open-market trade. The underlying 39,567 shares will vest in twelve equal monthly installments beginning on June 12, 2026, subject to his continued service.
Sagimet Biosciences Inc. director Jennifer Jarrett reported a grant of stock options on Series A Common Stock. She received options for 39,567 shares at an exercise price of $6.48 per share, all held as a direct derivative position following the transaction.
According to the terms, the shares underlying this option will vest and become exercisable in twelve equal monthly installments following June 12, 2026, conditioned on her continued service on each vesting date. The option expires on June 11, 2036, providing a long-dated equity incentive aligned with her board role.
Sagimet Biosciences Inc. director Elizabeth A. Grammer received a grant of stock options covering 39,567 shares of Series A Common Stock. The options have an exercise price of $6.48 per share and expire on June 11, 2036.
The shares underlying this option are scheduled to vest in twelve equal monthly installments following June 12, 2026, contingent on her continued service on each vesting date. This is a compensation-related award and does not reflect any open-market buying or selling of Sagimet stock.
Sagimet Biosciences Inc. granted director Kemble George a stock option covering 39,567 shares of Series A Common Stock at an exercise price of $6.48 per share. The option expires on June 11, 2036 and represents 39,567 derivative shares held after this grant.
According to the award terms, the shares underlying this option vest in twelve equal monthly installments following June 12, 2026, conditioned on his continued service on each vesting date.
Sagimet Biosciences Inc. director Anne M. Phillips received a grant of stock options covering 39,567 shares of Series A Common Stock at an exercise price of $6.48 per share. These options were awarded as compensation and are held directly.
The options vest and become exercisable in twelve equal monthly installments following June 12, 2026, contingent on her continued service on each vesting date. Following this grant, she holds stock options for 39,567 underlying shares, all from this award.
Sagimet Biosciences granted its Chief Financial Officer, Thierry Chauche, a stock option to acquire 50,000 shares of Series A Common Stock. The option has a $7.27 per-share exercise price and expires on May 27, 2036.
According to the filing, these options vest in 48 equal monthly installments beginning after May 28, 2026, contingent on his continued service. Following this grant, Chauche holds 50,000 stock options directly, reflecting routine equity-based compensation rather than an open-market transaction.
Sagimet Biosciences Inc. reported that Chief Medical Officer Andreas Grauer received a grant of stock options. The grant covers 35,000 Stock Options (Right to Buy), each exercisable for one share of Series A Common Stock at an exercise price of $7.27 per share.
The options vest in forty-eight equal monthly installments starting on May 28, 2026, conditioned on Dr. Grauer’s continued service on each vesting date. Following this grant, the filing shows Dr. Grauer directly holding 35,000 options under this award.
Sagimet Biosciences Inc. reported that Chief Legal & Admin. Officer Elizabeth Rozek received a grant of stock options as part of her compensation. She was awarded 100,000 stock options, each giving the right to buy one share of Series A common stock at an exercise price of $7.27 per share. These options expire on May 27, 2036. According to the terms, the shares underlying this option will vest in 48 equal monthly installments beginning after May 28, 2026, contingent on her continued service, and her reported derivative holdings after this grant total 100,000 options.
Sagimet Biosciences Inc. reported that President & CEO David Happel received a grant of stock options covering 300,000 shares of Series A common stock. The options have an exercise price of $7.27 per share and were awarded at no cost to him.
These options vest in forty-eight equal monthly installments starting on May 28, 2026, contingent on his continued service. After this grant, he holds options on 300,000 shares according to the filing. The transaction reflects equity-based compensation rather than an open-market purchase or sale.
Sagimet Biosciences reported that Chief Medical Officer Andreas Grauer received a grant of stock options covering 264,759 shares of Series A common stock. The options have an exercise price of $6.44 per share and expire on April 19, 2036.
According to the vesting terms, 25% of the underlying shares vest on April 20, 2027, with the remaining 75% vesting in 36 equal monthly installments, contingent on continued service. Following this grant, Grauer holds derivative rights over 264,759 shares through this option award.
Rozek Elizabeth reported acquisition or exercise transactions in this Form 4 filing.
Sagimet Biosciences Inc. reported that Chief Legal & Administrative Officer Elizabeth Rozek received new equity awards. She was granted an option to buy 88,000 shares of Series A Common Stock, vesting in 48 equal monthly installments starting February 19, 2026. She was also awarded 44,000 restricted stock units, each representing one share of Series A Common Stock, vesting in four equal annual installments from the same date, contingent on continued service.
Sagimet Biosciences Chief Medical Officer Eduardo Bruno Martins reported equity awards that increase his direct holdings. He received a stock option covering 88,000 shares of Series A Common Stock at an exercise price of $0.00 per share, and a separate grant of 44,000 shares of Series A Common Stock in the form of restricted stock units (RSUs).
The RSUs will vest in four equal annual installments after February 19, 2026, contingent on continued service. The stock option will vest in forty-eight equal monthly installments after the same date, also subject to continued service. Following these transactions, his reported direct ownership of Series A Common Stock is 147,296 shares, and he holds options for 88,000 shares.
Sagimet Biosciences President & CEO and director David Happel reported awards of equity-based compensation. He was granted 256,000 stock options with an exercise right to buy Series A Common Stock at $0.00 per share, and 128,000 restricted stock units (RSUs) for Series A Common Stock.
The RSUs vest in four equal annual installments following February 19, 2026, conditioned on his continued service. The options vest in forty-eight equal monthly installments after the same date, also tied to continued service. Following the RSU grant, his reported Series A Common Stock holdings total 805,621 shares.
Sagimet Biosciences Inc. reported that its Chief Financial Officer, Thierry Chauche, received new equity awards. He was granted a stock option for 88,000 shares at an exercise price of $0.0000 per share, which will vest in forty-eight equal monthly installments following February 19, 2026, subject to continued service.
Chauche also acquired 44,000 shares of Series A Common Stock in the form of restricted stock units. Each RSU represents one share and will vest in four equal annual installments following February 19, 2026, contingent on his continued service on each vesting date. After this award, his directly held Series A Common Stock totaled 59,688 shares.
Sagimet Biosciences Inc. President & CEO and director David Happel reported an automatic sale of Series A Common Stock. On 02/10/2026, 12,101 shares were sold at $5.3603 per share to cover tax withholding obligations related to vesting restricted stock units. After this transaction, he beneficially owned 677,621 shares directly. The filing notes these tax-related sales were automatic and not at his discretion.
Sagimet Biosciences Chief Financial Officer Thierry Chauche reported an automatic sale of Series A Common Stock largely tied to tax obligations. On February 10, 2026, he sold 1,312 shares at $5.3603 per share in an open-market transaction.
According to the disclosure, the shares were required to be sold to cover tax withholding arising from the vesting of restricted stock units, and the sales were automatic rather than discretionary. After this transaction, Chauche directly beneficially owned 15,688 shares of Sagimet Biosciences common stock.
Sagimet Biosciences’ Chief Medical Officer reports automatic share sale to cover taxes. Martins Eduardo Bruno sold 3,640 shares of Series A Common Stock on February 10, 2026 at an average price of $5.3602 per share in an open-market transaction.
According to the footnote, the sale was required to cover tax withholding obligations tied to vesting restricted stock units and was executed automatically, not at his discretion. After this transaction, he directly beneficially owned 103,296 shares of Sagimet Biosciences Inc.
Sagimet Biosciences Inc. Chief Legal & Admin. Officer Elizabeth Rozek reported an automatic sale of 2,622 shares of Series A Common Stock on February 10, 2026 at an average price of $5.3602 per share. After this tax-related sale, she beneficially owns 190,959 shares directly.
The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, and the filing states that these sales were automatic and not made at her discretion.
Sagimet Biosciences Inc. (SGMT) reported an insider transaction by a director and Executive Chairman. On 11/20/2025, the reporting person sold 37,688 shares of Series A common stock in an open-market sale coded as "S." The weighted average sale price was $7.6942 per share, with individual trades executed between $7.27 and $8.15.
After this transaction, the insider beneficially owned 81,005 shares of Sagimet Biosciences common stock in direct ownership. The sale was carried out under a Rule 10b5-1 trading plan adopted on August 21, 2025, which is a pre-arranged plan designed to allow insiders to sell shares according to predetermined instructions.
Sagimet Biosciences (SGMT) disclosed an insider equity award. On 11/04/2025, the Chief Legal & Admin. Officer received 9,855 restricted stock units at $0.00 and a stock option for 13,367 shares at an exercise price of $7.61, both granted in connection with a promotion.
The RSUs vest in four equal annual installments following November 4, 2025. The option vests over 48 equal monthly installments following November 4, 2025 and has an expiration date of 11/03/2035. After these grants, 193,581 Series A Common shares were beneficially owned directly, and 13,367 options were held.